Novavax, Inc. — Form 10-Q Summary
Reporting period: Quarter ended September 30, 2021; filed November 4, 2021. Financial statements are unaudited. Novavax is a biotechnology company focused on vaccines, principally COVID-19 candidate NVX-CoV2373, with influenza and other vaccine programs.
Financial performance and position
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | $178.8 million | $157.0 million | $924.1 million | $195.9 million |
| Research and development expense | $408.2 million | $294.1 million | $1,571.6 million | $345.8 million |
| General and administrative expense | $77.8 million | $56.9 million | $214.1 million | $84.0 million |
| Operating loss | $307.1 million | $193.9 million | $861.6 million | $233.9 million |
| Net loss | $322.4 million | $197.3 million | $897.5 million | $240.7 million |
| Net loss per share | $4.31 | $3.21 | $12.13 | $4.39 |
Revenue growth reflected increased OWS contract activity and, for the first time, partner-related royalties. Q3 royalties were $39.9 million and nine-month royalties were $63.4 million. Nine-month government-contract revenue was $720.7 million, predominantly from OWS. Costs rose substantially with NVX-CoV2373 development and manufacturing activity; management attributed the higher net loss chiefly to these activities, with revenue growth partly offsetting the expense increase. The company had no commercial product sales reported in these results.
Cash flow and liquidity: Cash, cash equivalents and restricted cash totaled $1.947 billion at September 30, 2021, versus $648.7 million at year-end 2020; the company also reported no marketable securities at quarter-end. Working capital was $420.8 million. Nine-month operating cash flow was positive $665.4 million, primarily because of advance-purchase payments recorded as deferred revenue, rather than operating profitability. Investing cash flow was positive $116.5 million and financing cash flow was positive $522.4 million, including $564.9 million net proceeds from common-stock sales. Capital expenditures were $41.1 million.
Debt and obligations: Convertible notes had $325 million principal, a 3.75% coupon and a February 2023 maturity; carrying value was $323.1 million. The notes’ estimated fair value was $559.7 million. Finance-lease liabilities were $104.0 million current, with none reported as non-current at quarter-end. Deferred revenue was $1.262 billion, primarily advance payments under purchase agreements; approximately $7.2 billion of transaction price related to unsatisfied or partially unsatisfied performance obligations, expected to be fulfilled within 12 months. Some advances may be refundable if agreements terminate following missed regulatory milestones.
Changes versus comparable periods
- Nine-month revenue increased $728.2 million year over year, while nine-month R&D expense increased $1.226 billion and net loss widened by $656.8 million.
- Q3 revenue rose $21.8 million, but net loss widened by $125.1 million. R&D expense increased $114.1 million year over year.
- Shares outstanding increased: weighted-average shares were 74.745 million in Q3 and 73.972 million for the nine-month period, versus 61.554 million and 54.810 million, respectively, in 2020. Common-stock sales generated $564.9 million net proceeds in the first nine months of 2021.
- Deferred revenue rose to $1.262 billion from $273.2 million at year-end 2020, chiefly reflecting customer advance payments. The company’s OWS contract ceiling increased by $52.9 million to approximately $1.8 billion, while authorized funding and scope remained $1.75 billion.
Outlook, commentary and key risks
- Management reported global NVX-CoV2373 manufacturing capacity of approximately 100 million doses per month at Q3-end, expected to reach approximately 150 million monthly by Q4-end and exceed 2 billion annual doses in 2022. These are expectations, not achieved results.
- The company expected to submit its complete U.S. FDA regulatory package by year-end 2021, subject to ongoing CMC work and alignment on analytical methods. The U.S. government had instructed Novavax to prioritize FDA alignment before additional U.S. manufacturing and said it would not fund additional U.S. manufacturing until that alignment was achieved.
- Regulatory progress reported after quarter-end included Indonesia’s EUA in November, completion of EMA rolling submissions, and filings or rolling submissions in several other markets. These subsequent events do not represent quarter-end approvals; U.S. authorization had not been obtained as of the filing.
- Management cited positive Phase 3 efficacy results, including 90.4% overall efficacy in the U.S./Mexico trial and 89.7% in the UK trial. Commercialization remains dependent on regulatory authorization, validated assays, manufacturing consistency and partner delivery.
- Key risks include regulatory or manufacturing delays, raw-material and third-party capacity constraints, competition and uncertain demand, failure to meet purchase-agreement timelines, potential repayment of refundable advances, continued operating losses and possible need for additional financing. Additional equity financing could dilute shareholders. The company reported an accumulated deficit of $2.8 billion.
- A stockholder derivative action concerning 2020 equity awards was stayed after shareholder ratification; the plaintiff sought $1.5 million in attorneys’ fees, which defendants intended to oppose. The filing reported no material off-balance-sheet arrangements. Management concluded disclosure controls were effective at the reasonable-assurance level.
Most important facts for investors to verify
- Whether FDA and other regulatory reviews are completed on time, and whether assay validation and manufacturing data satisfy regulators.
- Whether the projected production capacity is achieved and translates into reliable, timely deliveries by Novavax and its manufacturing partners.
- Terms, refundability and termination conditions of advance-purchase agreements, including the outstanding deferred revenue and additional payment milestones.
- Cash use and financing needs as R&D, manufacturing, capital expenditure and commercialization costs continue; assess potential dilution and the 2023 notes maturity.
- Whether reported trial efficacy and safety results support approvals and market acceptance amid evolving variants, competition and changing vaccine demand.